MingMed posts positive Phase II QA102
- MingMed Biotechnology said on May 5 that its oral dry-AMD drug QA102 showed positive Phase II signals in an ARVO 2026 presentation in Denver. - In 150 patients, the 400 mg twice-daily arm cut drusen-volume growth rate 118.2% and geographic-atrophy growth 42.7% versus placebo, despite a missed primary endpoint. - That matters because intermediate dry AMD has no approved therapy to slow progression, and QA102 is being pitched as an oral option.
Age-related macular degeneration is one of those diseases where timing matters a lot. By the time dry AMD becomes advanced, vision loss can be permanent, but the earlier intermediate stage still has almost no approved drugs aimed at slowing the slide. That is why MingMed’s Phase II update on QA102 got attention this week at ARVO 2026 in Denver — not because the trial was cleanly perfect, but because an oral drug showed signs it might be doing something in a stage of disease that drugmakers have mostly failed to crack. (prnewswire.com) ### What is QA102 trying to treat? QA102 is being tested in intermediate dry AMD, the stage where patients develop large drusen — those fatty deposits under the retina — and pigment changes that raise the risk of progressing to advanced disease. MingMed framed this as the biggest untreated part of the dry-AMD population. The company’s materials say nearly 7% of Americans age 65 and older are affected. (prnewswire.com) ### Why is an oral drug a big deal? Most retina drugs people know are injections into the eye, and those are generally used later, especially in wet AMD or in geographic atrophy once dam(prnewswire.com) raise the ceiling if the effect is real. (prnewswire.com) ### What did the trial actually do? The study, listed as NCT05536752, was a randomized, double-masked, placebo-controlled Phase II trial in 150 subjects with intermediate atrophic AMD. Patients were assigned 1:1:1 to QA102 at 200 mg, QA102 at 400 mg, or placebo, taken twice daily for up to 15 months. MingMed presented 12-month treatment data at ARVO. (prnewswire.com) ### So what were the headline numbers? The 400 mg arm is where the signal showed up. MingMed said mean change in drusen volume was reduced 59.2% versus placebo after 12 months. More eye-catching, the growth rate in drusen volume was reduced 118.2% with a p-value of 0.017, and the growth rate in square-root transformed geographic atrophy area was reduced 42.7% with a p-value of 0.026. Those are the numbers carrying the story. (prnewswire.com) ### What is the catch? The primary endpoint missed. That is the part investors and retina specialists will stare at first, because positive secondary endpoints matter less when the main (prnewswire.com)ctively. (prnewswire.com) ### Did safety look acceptable? From what MingMed disclosed publicly, yes — but only at a high level. The company said QA102 showed an acceptable safety profile. What is missing right now is a fuller breakdown of adverse events, discontinuations, and whether any side effects were dose-related. For an oral chronic therapy in an older population, that detail will matter almost as much as efficacy. (prnewswire.com) ### Why does this stand out in dry AMD? Because intermediate dry AMD is the awkward middle zone. It is common, it clearly matters, but it has been hard to design drugs that show convinci(prnewswire.com)why this dataset got an oral slot at ARVO. (prnewswire.com) ### What happens next? The next step is straightforward — a larger, better-powered study with a cleaner shot at a primary endpoint that regulators would care about. If QA102 can repeat these signals, the idea of treating dry AMD earlier with a pill starts to look real. If it cannot, this week’s update will read as another almost-story in a field full of them. (prnewswire.com) For now, the news is not that MingMed solved dry AMD. It is that an oral drug produced enough signal in a neglected stage of disease to keep the idea alive — and in this corner of ophthalmology, that is already meaningful.
